Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.
Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch "Vants" - nimble and focused biopharmaceutical and health technology companies.
Enabling normal lives for patients with autoimmune diseases
Leading innovation in medical dermatology
Delivering results through RNA therapeutics
Degrading errant proteins to elevate patient health
Developing a new therapy for sarcoidosis
Developing a novel endolysin for bacterial infections
Developing bispecific antibodies for solid tumors
Developing gene therapies for rare diseases
Shifting the paradigm in clinical trial intelligence
Expanding the boundaries of in-silico drug design
Organizing the world's healthcare data
Developing novel and innovative cellular therapeutics in Asia
Roivant Health is our platform for founding and funding innovative digital health businesses.
As an integrated pharma-tech business, we hope to lead the transition to a more data-driven, patient-centric, and value-oriented health system. Companies we have built include Datavant, now the nation's largest health data ecosystem, and Lokavant, a leading clinical trial intelligence company creating operational transparency for sponsors and CROs.
We have a diverse pipeline of investigational drugs across our family of companies.
Roivant empowers a global team of innovators in the biopharmaceutical industry to expand the world of treatable conditions.
With offices in New York City, Boston, and Basel as well as remote working options, collaborating on a better future together has never been easier.
Chief Executive Officer
Eric Venker, MD
President & Chief Operating Officer
President & Chief Investment Officer
Frank Torti, MD
Chief Financial Officer
Chief Accounting Officer
Woody Sherman, PhD
Chief Computational Scientist
EVP, Roivant Health
Chief Operating Officer, Roivant Platforms
Pete Salzmann, MD, MBA
William Chou, MD
CEO, Roivant Social Ventures
John Xu, MD
Bill Macias, MD, PhD
Chief Medical Officer, Immunovant
Chief Commercial Officer, Dermavant
Chris Van Tuyl
General Counsel, Dermavant
Christopher Winter, PhD
Head of Portfolio Strategy, Roivant Discovery
David Rubenstein, MD, PhD
Chief Scientific Officer, Dermavant
Huafeng Xu, PhD
CTO, Roivant Discovery
James Heyes, PhD
Chief Scientific Officer, Genevant
Chief Operating Officer, Lokavant
Julia G. Butchko
Chief Development & Technology Officer, Immunovant
Pamela Carroll, PhD
Chief Business Officer, Roivant Discovery
Chief Legal Officer, Genevant
Philip Brown, MD, JD
Chief Medical Officer, Dermavant
Stephanie Lee Griffin
Chief Business Officer, Lokavant
Founder, Executive Chairman
James C. Momtazee
Roivant's drug discovery capabilities are driven by our industry-leading computational platform, which combines preeminent physics-based simulation tools with machine learning to generate unprecedented predictive power that can tackle previously intractable challenges.
The tight integration of our computational platform with our broad experimental capabilities and deep drug discovery experience enables the rapid design and optimization of new drugs to address a wide range of targets for diseases with high unmet need.
Roivant Sciences, Inc.
151 W 42nd Street
New York, NY 10036
Roivant Sciences, Inc.
451 D Street
Boston, MA 02210
Roivant Sciences GmbH